Overview of Medical Device Registration in Indonesia

Leave a comment

The Indonesian medical devices market is one of the largest in Southeast Asia and continues to grow at an accelerating pace as a result of the country’s population growth, increased demand for sophisticated medical technologies, and improved healthcare delivery systems. Indonesia’s regulation of medical devices is managed by the National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan). The BPOM oversees the registration and market release of all medical devices as well as the regulation and enforcement of medical device regulations.

Regulatory Authority and Legal Framework

Medical devices in Indonesia are regulated by the BPOM and are subject to the oversight of the Ministry of Health (MoH). Regulations governing the medical device industry include the classification, registration, distribution, and post-market surveillance of medical devices, as well as product evaluation and post-market control.

Definition and Scope of Medical Devices

In Indonesia, a medical device is defined as any instrument, apparatus, machine, implant, in vitro diagnostic product, or similar item used for diagnosing, treating, monitoring, or alleviating human injury or disease.

Device Classification

Medical devices are classified by their level of risk and are classified according to the same risk-based criteria used by many other countries:

  • Class A: Low risk
  • Class B: Low–moderate risk
  • Class C: Moderate–high risk
  • Class D: High risk

The risk classification determines the level of technical documentation, clinical evidence requirements, and depth of BPOM review.

Who Can Hold a Medical Device Registration in Indonesia

Indonesia applies strict rules on who may act as a medical device registration holder. Only the following entities are permitted to register medical devices with BPOM:

  • Indonesian subsidiaries of foreign manufacturers, or
  • Indonesian-licensed medical device distributors

Foreign manufacturers without a legal entity in Indonesia cannot directly hold product registrations. As a result, registration ownership is typically held by a local distributor, which can limit the foreign manufacturer’s control over its product approvals, lifecycle management, and sales and marketing strategy.

To address this issue, some independent third-party service providers have established so-called “dummy” distributor licenses. Under this arrangement, the third party holds a valid Indonesian distributor license and acts as the official registration holder on behalf of the foreign manufacturer. The dummy distributor imports the products, stores them in an Indonesian warehouse, and then releases them to the commercial (real) Indonesian distributor for sale and distribution.

This structure allows foreign medical device companies without an Indonesian office to retain independent control over their product registrations, rather than tying registrations to a commercial distributor. It also provides greater flexibility when changing distributors and can reduce long-term regulatory and commercial risk.

Registration Pathways

All medical devices must be registered through BPOM’s electronic registration system prior to commercialization. The registration holder, whether a subsidiary, distributor, or dummy distributor, must submit the application and maintain regulatory responsibility throughout the product lifecycle.

The registration process generally includes:

  • Product classification confirmation
  • Submission of administrative and technical documentation
  • BPOM review and evaluation
  • Issuance of a distribution permit (NIE – Nomor Izin Edar)

Documentation Requirements

Documentation requirements vary by risk class. However, they share a lot of overlap with the ASEAN Common Submission Dossier Template (CSDT) and typically include:

  • Administrative documents (company licenses, Letters of Authorization, distribution agreements)
  • Product description and intended use
  • Technical specifications and design information
  • Evidence of compliance with essential safety and performance principles
  • Quality Management Certificate
  • Risk management documentation
  • Clinical evaluation or performance data, where applicable
  • Labeling and instructions for use in Bahasa Indonesia

Higher-risk devices (Classes C and D) are subject to more extensive technical and clinical review.

Quality Management System Requirements

Manufacturers need to establish a Quality Management System (QMS). Certification according to ISO 13485 is considered proof of compliance.

Review Timelines and Validity

The timelines for reviewing are determined by the classification of the device, the volume of information submitted in the dossier, and whether any additional clarification is needed during the review process. After receiving approval, the distribution permit is valid for 2 to 5 years and must be renewed before it expires.

Post-Market Obligations

Registration holders are responsible for post-market compliance, including:

  • Post-market surveillance and vigilance reporting
  • Reporting of adverse events and field safety corrective actions
  • Cooperation with recalls and corrective actions
  • Compliance with BPOM inspections and market sampling activities

BPOM actively monitors marketed devices to ensure ongoing safety and quality.

Emerging Trends and Regulatory Developments

Indonesia continues to strengthen its medical device regulatory system, with increasing alignment to international standards and enhanced post-market oversight. The country’s attainment of World Health Organization (WHO) Listed Authority (WLA) status reflects growing regulatory maturity and supports greater international collaboration.

Conclusion

Medical device registration in Indonesia follows a structured framework that emphasizes both pre-market evaluation and post-market control. While foreign manufacturers face restrictions on direct registration ownership, mechanisms such as local subsidiaries or independent dummy distributor arrangements provide viable pathways to market entry. Indonesia remains a strategically important market for medical device companies seeking growth in the rapidly growing ASEAN region.

Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.